Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Fate Therapeutics (FATE) EBITDA (2016 - 2025)

Historic EBITDA for Fate Therapeutics (FATE) over the last 14 years, with Q3 2025 value amounting to -$32.2 million.

  • Fate Therapeutics' EBITDA rose 3072.32% to -$32.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$156.8 million, marking a year-over-year increase of 1137.44%. This contributed to the annual value of -$186.0 million for FY2024, which is 1694.34% down from last year.
  • Fate Therapeutics' EBITDA amounted to -$32.2 million in Q3 2025, which was up 3072.32% from -$34.2 million recorded in Q2 2025.
  • Fate Therapeutics' EBITDA's 5-year high stood at -$17.7 million during Q1 2023, with a 5-year trough of -$83.4 million in Q3 2022.
  • Its 5-year average for EBITDA is -$49.7 million, with a median of -$46.4 million in 2024.
  • In the last 5 years, Fate Therapeutics' EBITDA surged by 7392.52% in 2023 and then plummeted by 17280.6% in 2024.
  • Over the past 5 years, Fate Therapeutics' EBITDA (Quarter) stood at -$69.3 million in 2021, then grew by 20.7% to -$55.0 million in 2022, then grew by 20.66% to -$43.6 million in 2023, then fell by 20.9% to -$52.7 million in 2024, then surged by 39.0% to -$32.2 million in 2025.
  • Its last three reported values are -$32.2 million in Q3 2025, -$34.2 million for Q2 2025, and -$37.7 million during Q1 2025.